Jun 02, 2022 / 04:30PM GMT
Phil Nadeau - Cowen and Company, LLC - Analyst
Good afternoon and welcome once again to Cowen and Company's Third Annual Oncology Innovation Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowen. And it's my pleasure to moderate a fireside discussion with Syndax Pharmaceuticals. We have with us today Michael Metzger, the Chief Executive Officer; and Anjali Ganguli, the Chief Business Officer.
And with that, we'll dive right into questions.
Questions and Answers:
Phil Nadeau - Cowen and Company, LLC - AnalystMost investor focus is on revumenib or SNDX-5613. Michael, could you give a brief summary of the efficacy data that were presented at ASH 2021 from AUGMENT-101 for those who are less familiar?
Michael Metzger - Syndax Pharmaceuticals, Inc. - CEO & Director
Sure. Pleasure to be here today. Phil. Thanks for having us and happy to summarize the data for you. So at ASH last December, we shared data from the Phase 1 portion of AUGMENT-101 testing revumenib, which is our menin inhibitor
Trustpilot
